By deadline
Latest
Nouscom raises €120M Series D to intercept cancer before it startsLinkener raises €7.5M to digitise business energy managementCoComply raises £1.9M to govern the hidden contractor workforceVessla raises $3.3M pre-seed for AI agents in property managementAll funding coverage →Browse the database
Latest
Pick the LP first, then the 2027 conferenceBessemer Venture Partners closes $5.75B, mostly for growthQuantumLight Closes $500M Fund II – and Algorithmic VC Stops Being an ExperimentThe EIF’s €15B ETCI 2 Is Europe’s Biggest Bet Yet on Fixing the Scaleup GapAll investors coverage →By ticket size
By country
Strategic corporate venture capital arm of Merck KGaA, investing globally in innovative technologies and products with the potential to significantly impact Merck's core business areas, with a significant focus on early-stage investing and company creation.
| Company | Round | Date | Round size |
|---|---|---|---|
| Nouscom Basel, Switzerland | Series D+ | Oct 2026 | €120M |
